First Data From Subcutaneous Epcoritamab + Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) for First-Line Diffuse Large B-Cell Lymphoma (DLBCL): EPCORE NHL-5

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Clinical Lymphoma Myeloma & Leukemia

Topics

Medicine

Cancer Oncology

Dermatology

Internal Medicine

Pathology And Forensic Medicine

Show all topics

DOI

10.1016/s2152-2650(24)00821-8